GLP-1 News & Market Updates
Follow meaningful developments in GLP-1 treatment, pricing, insurance, regulation, compounding and access. GLP-1 Primer focuses on developments with practical relevance to patients and consumers rather than attempting to cover every industry headline.
FDA Approves Foundayo (orforglipron) as First Once-Daily Oral GLP-1 for Obesity
The FDA approved Eli Lilly's Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for the treatment of obesity and overweight with weight-related comorbidities. Unlike other oral GLP-1 options, it does not require specific food or water restrictions for administration.
FDA Clarifies Enforcement Policy as GLP-1 Supply Stabilizes
The FDA has signaled a shift in enforcement regarding compounded GLP-1 medications, stating that as national supply stabilizes, compounders should transition away from the routine production of these drugs. The agency has issued multiple warning letters to entities making unsubstantiated claims about compounded products.
Medicare GLP-1 Bridge Demonstration Program Initiated
Effective July 1, 2026, Medicare launched the 'Medicare GLP-1 Bridge,' a short-term demonstration program designed to provide eligible Medicare beneficiaries with access to GLP-1 medications.
